CEO Simon Tomlinson told BioWorld Today that Akriveia Therapeutics LLC's approach "exploits the differential biochemistry of the tumor micro-environment to activate an otherwise inert biologic molecule in the vicinity of the tumor," a rational-design strategy to "bioengineer the optimal tumor-targeted biologic."